Michael Geffner - 22 Oct 2025 Form 4 Insider Report for Immunovant, Inc. (IMVT)

Reporting relationship: Chief Medical Officer
Issuer ticker: IMVT
Reported as of: 22 Oct 2025
Net transaction value: -$49,383
SEC form: 4
Accepted by SEC: 24 Oct 2025, 16:38:29 UTC
Prior SEC filing: 10 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ Tiago Girao, attorney-in-fact for Michael Geffner

Key filing fact

Michael Geffner filed Form 4 for Immunovant, Inc. (IMVT) on 24 Oct 2025.

Key facts

This page summarizes Michael Geffner's Form 4 filing for Immunovant, Inc. (IMVT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 24 Oct 2025, 16:38.

Change

Previous filing in this sequence was filed on 10 Oct 2025.
Current net transaction value: -$49,383.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002007249 Primary reporting owner

Geffner Michael

Relationship: Chief Medical Officer
Address: C/O IMMUNOVANT, INC., 320 W 37TH STREET, 6TH FLOOR, NEW YORK
Signature: /s/ Tiago Girao, attorney-in-fact for Michael Geffner
Signature date: 24 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IMVT transaction

Common Stock

Sale

Transaction value: $49,383
Shares: -2,595
Change %: -1.2%
Price: $19.03
Shares after: 217,958
Date: 22 Oct 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On January 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 3 filed on January 16, 2024, of which 6,250 of these RSUs vested on October 17, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Footnote F2

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.03 - $19.20 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.